The Zhitong Finance App learned that Lycia Therapeutics, a biotech company focused on treating allergies and autoimmune diseases, has expanded its upcoming initial public offering (IPO) in the US. According to a statement released by the company on Thursday, Lycia will issue 17.64 million shares at a price of $18 each to raise $3175 million. According to an earlier document, the biotech company originally planned to issue 14.7 million shares at a price of 16 to 18 US dollars each.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.